ANAB ANAPTYSBIO, INC

BEARISH Impact: 5/10 144
Horizon weeks Filed Jun 10, 2026 Processed 6d 11h ago SEC 0001950047-26-005897
Form 144 — notice of proposed sale of securities
Latest settled — T+1d
ANAB ▲ +3.37% at T+1d
SHORT call ✗ call lost -3.37% · α vs SPY -2.83% · entry $54.24 → $56.07
Next anchor: T+5d in 4h
Currently $57.61 · -6.21% from $54.24 entry (call sign-flipped)
Entry anchored
Jun 10, 03:59 PM ET
via Databento tick
T+1d
+3.37%
call -3.37% · α -2.83%
$56.07
settled 6d ago
T+5d
call — · α —
in 4h
T+20d
call — · α —
in 22d
T+60d
call — · α —
in 3mo

Price Chart

Loading chart...

Executive Summary

Dennis Mulroy, an officer of AnaptysBio, filed a Form 144 on June 10, 2026, indicating intent to sell 20,000 shares (~$1.05M). This is part of a heavy selling pattern with over 250,000 shares sold in the past month, representing a significant insider distribution. The sustained selling by a key officer raises caution despite strong analyst consensus.

Actionable Insight

The repeated insider selling by a key officer is a bearish signal, though the stock has shown resilience. Monitor for additional 144 filings or Form 4 submissions indicating further sales. Consider the pattern as a potential headwind to near-term price appreciation.

Key Facts

  • Officer Dennis Mulroy intends to sell 20,000 shares valued at ~$1,046,560.
  • Mulroy has sold over 250,000 shares in the past month (since May 15, 2026), totaling roughly $13M.
  • The 144 filing is for shares acquired via stock option exercise.
  • AnaptysBio has a market cap of $1.5B and 94% analyst bullish rating.

Financial Impact

Officer Dennis Mulroy proposes to sell 20,000 shares worth ~$1.05M, part of a selling spree totaling over 250,000 shares valued at ~$13M in the past month (May 15 – June 10, 2026).

dilutioninsider selling volume

Risk Factors

  • Continued insider selling could signal management's lack of confidence ahead of upcoming catalysts or earnings.
  • The selling volume may create technical overhang, especially if open-market sales persist.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
94% bullish (17 analysts)

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001950047-26-005897
Document: 0001950047-26-005897-index.html0001950047-26-005897
Document: 0001950047-26-005897.txt0001950047-26-005897
18 reports for ANAB
Performance horizon
58% Hit rate 7 of 12 directional calls best @ T+60▲ +41.26%Mar 3, 2026
Filters
Rows
Reports for ANAB — sortable, filterable
Type Now
Jun 15, 2026
1d ago
144
BEARISH ★ 6/10
$59.48 awaiting T+1awaiting T+1$57.61 (+3.14%)
Jun 11, 2026
5d ago
144
BEARISH ★ 6/10
$56.07 $59.51▼ −6.14%▼ −4.37%$57.61 (−2.75%)
Jun 10, 2026
6d ago
144
BEARISH ★ 5/10
$54.24 $56.07▼ −3.37%▼ −2.83%$57.61 (−6.21%)
Jun 8, 2026
8d ago
144
BEARISH ★ 5/10
$51.63 $52.10▼ −0.91%▼ −2.49%$57.61 (−11.58%)
Jun 5, 2026
11d ago
144
BEARISH ★ 5/10
$51.36 $51.63▼ −0.53%▼ −0.82%$57.61 (−12.17%)
Jun 5, 2026
11d ago
144
BEARISH ★ 5/10
$50.37 $51.36▼ −1.97%▼ −1.74%$57.61 (−14.37%)
Jun 3, 2026
13d ago
144
BEARISH ★ 5/10
$51.67 $50.37▲ +2.52%▼ −0.08%$57.61 (−11.50%)
Jun 1, 2026
15d ago
144
BEARISH ★ 5/10
$51.26 $51.24▲ +0.04%▼ −0.68%$57.61 (−12.39%)
May 29, 2026
18d ago
8-K
NEUTRAL ★ 2/10
$53.14 $51.26▼ −3.54%▼ −3.69%$57.61 (+8.41%)
May 28, 2026
19d ago
144
NEUTRAL ★ 3/10
$55.67 $53.14▼ −4.54%▼ −4.80%$57.61 (+3.48%)
Showing 10 of 18

US Market Status

Market Closed — Opens in 5h 39m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access